Advertisement
U.S. markets open in 3 hours 37 minutes
  • S&P Futures

    5,205.75
    -9.00 (-0.17%)
     
  • Dow Futures

    39,171.00
    -52.00 (-0.13%)
     
  • Nasdaq Futures

    18,193.25
    -38.25 (-0.21%)
     
  • Russell 2000 Futures

    2,042.80
    -7.00 (-0.34%)
     
  • Crude Oil

    82.50
    -0.22 (-0.27%)
     
  • Gold

    2,157.00
    -7.30 (-0.34%)
     
  • Silver

    25.10
    -0.16 (-0.63%)
     
  • EUR/USD

    1.0840
    -0.0037 (-0.34%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • Vix

    14.59
    +0.26 (+1.81%)
     
  • GBP/USD

    1.2674
    -0.0055 (-0.43%)
     
  • USD/JPY

    150.6750
    +1.5770 (+1.06%)
     
  • Bitcoin USD

    63,797.27
    -4,151.19 (-6.11%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,718.34
    -4.21 (-0.05%)
     
  • Nikkei 225

    40,003.60
    +263.20 (+0.66%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NERV, QSR and TRIT

NEW YORK, NY / ACCESSWIRE / January 19, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Minerva Neurosciences, Inc. (NASDAQ:NERV)
Class Period: May 15, 2017 - November 30, 2020
Lead Plaintiff Deadline: February 8, 2021

The NERV lawsuit alleges that throughout the class period, Minerva Neurosciences, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the truth about the feedback received from the FDA concerning the “end-of-Phase 2” meeting; (ii) the Phase 2b study did not use the commercial formulation of roluperidone and was conducted solely outside of the United States; (iii) the failure of the Phase 3 study to meet its primary and key secondary endpoints rendered that study incapable of supporting substantial evidence of effectiveness; (iv) the Company's plan to use the combination of the Phase 2b and Phase 3 studies would be “highly unlikely” to support the submission of an NDA; (v) reliance on these two trials in the submission of an NDA would lead to “substantial review issues” because the trials were inadequate and not well-controlled; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in NERV: http://www.kleinstocklaw.com/pslra-1/minerva-neurosciences-inc-loss-submission-form?id=12249&from=1

Restaurant Brands International Inc. (NYSE:QSR)
Class Period: April 29, 2019 - October 28, 2019
Lead Plaintiff Deadline: February 19, 2021

The QSR lawsuit alleges Restaurant Brands International Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) the Company's Winning Together Plan was failing to generate substantial, sustainable improvement within the Tim Hortons brand; (2) the Tims Rewards loyalty program was not generating sustainable revenue growth as increased customer traffic was not offsetting promotional discounting; and (3) as a result, Defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis.

Learn about your recoverable losses in QSR: http://www.kleinstocklaw.com/pslra-1/restaurant-brands-international-inc-loss-submission-form?id=12249&from=1

Triterras, Inc., f/k/a Netfin Acquisition Corp. (NASDAQ:TRIT)
Class Period: August 20, 2020 - December 16, 2020
Lead Plaintiff Deadline: February 19, 2021

The complaint alleges Triterras, Inc., f/k/a Netfin Acquisition Corp. made materially false and/or misleading statements and/or failed to disclose that: (1) the extent to which Company's revenue growth relied on Triterras' relationship with Rhodium to refer users to the Kratos platform; (2) that Rhodium faced significant financial liabilities that jeopardized its ability to continue as a going concern; (3) that, as a result, Rhodium was likely to refer fewer users to the Company's Kratos platform; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in TRIT: http://www.kleinstocklaw.com/pslra-1/triterras-inc-f-k-a-netfin-acquisition-corp-loss-submission-form?id=12249&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/624847/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-NERV-QSR-and-TRIT

Advertisement